Last edition
News about "HIV Prevention "
US FDA Accepts Gilead's Once-Weekly Yeztugo for HIV Prevention
Gilead’s investigational once-weekly oral HIV prevention pill Yeztugo has been accepted for US FDA review, supported by strong clinical data showing high efficacy of lenacapavir in preventing HIV across 2 clinical trials. The therapy could become the first long-acting oral option for HIV prevention.
HIV Prevention | 16/06/2026 | By News Bureau
Dr. Reddy's, Hetero to Produce Affordable Generic Lenacapavir For HIV Prevention by 2027
Indian pharmaceutical companies Dr. Reddy’s Laboratories and Hetero Labs (Hetero) have signed landmark agreements to manufacture generic versions of lenacapavir, a revolutionary long-acting HIV prevention drug, which will be available at roughly USD 40 per patient per year in low- and middle-income countries (LMICs) starting in 2027.
HIV Prevention | 29/09/2025 | By Dineshwori | 817
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy